Biomedical Evidence Hierarchy

Peptide Evidence Level & Clinical Trial Checker

Distinguish between verified, FDA-approved Phase 3 human randomized controlled trials (RCTs) and early preclinical animal models. Understand the true statistical strength of clinical literature behind each compound.

Gold Standard Human Evidence

Tier 1: FDA-Approved Human Phase 3 RCTs

Supported by multi-center, double-blind, randomized controlled trials in thousands of human subjects (n > 1,000) demonstrating statistical efficacy and quantifiable safety profiles.

Compounds Classified in Tier 1:

SemaglutideMonograph

Trials: SUSTAIN 1-10, STEP 1-8, SELECT (n > 25,000)

Key Clinical Finding: 14.9% mean weight loss; 20% MACE CVD risk reduction

TirzepatideMonograph

Trials: SURPASS 1-6, SURMOUNT 1-4 (n > 15,000)

Key Clinical Finding: 20.9% mean weight loss; profound glycemic normalization

Bremelanotide (PT-141)Monograph

Trials: RECONNECT Trials (n=1,247)

Key Clinical Finding: Statistically significant improvement in HSDD desire scores

TesamorelinMonograph

Trials: Phase 3 Lipodystrophy Programs (n=806)

Key Clinical Finding: 15-18% reduction in visceral adipose tissue (VAT) via MRI

Clinical Hierarchy Standard: Evidence tiers reflect Oxford Centre for Evidence-Based Medicine (CEBM) criteria and FDA Center for Drug Evaluation and Research (CDER) standards. Developed under our Medical Review Policy.